MX2022016038A - Uso de cannabidiol en el tratamiento de la epilepsia. - Google Patents
Uso de cannabidiol en el tratamiento de la epilepsia.Info
- Publication number
- MX2022016038A MX2022016038A MX2022016038A MX2022016038A MX2022016038A MX 2022016038 A MX2022016038 A MX 2022016038A MX 2022016038 A MX2022016038 A MX 2022016038A MX 2022016038 A MX2022016038 A MX 2022016038A MX 2022016038 A MX2022016038 A MX 2022016038A
- Authority
- MX
- Mexico
- Prior art keywords
- cbd
- caffeine
- present
- extract
- cannabidiol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2009321.7A GB202009321D0 (en) | 2020-06-18 | 2020-06-18 | Use of cannabinoids in the treatment of epilepsy |
| PCT/GB2021/051520 WO2021255446A1 (en) | 2020-06-18 | 2021-06-16 | Use of cannabidiol in the treatment of epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016038A true MX2022016038A (es) | 2023-02-02 |
Family
ID=71838306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016038A MX2022016038A (es) | 2020-06-18 | 2021-06-16 | Uso de cannabidiol en el tratamiento de la epilepsia. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230225986A1 (https=) |
| EP (1) | EP4167980B1 (https=) |
| JP (1) | JP2023530500A (https=) |
| KR (1) | KR20230026337A (https=) |
| CN (1) | CN115916168A (https=) |
| AU (1) | AU2021291128A1 (https=) |
| CA (1) | CA3181694A1 (https=) |
| GB (2) | GB202009321D0 (https=) |
| MX (1) | MX2022016038A (https=) |
| TW (1) | TW202214217A (https=) |
| WO (1) | WO2021255446A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| AU2024300440A1 (en) * | 2023-07-25 | 2026-03-12 | Algorae Pharmaceuticals Ltd | Compositions and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015308546A1 (en) * | 2014-08-25 | 2017-04-13 | Clk Consult V/ Carsten Leonhard Knudsen | Device with compositions for delivery to the lungs, the oral mucosa and the brain |
| GB2531282A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US20180360771A1 (en) * | 2017-06-14 | 2018-12-20 | Yury Leon Shmerlis | Cannabidiol chewing gum |
| GB2568471B (en) | 2017-11-15 | 2022-04-13 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| CN109985042A (zh) * | 2017-12-29 | 2019-07-09 | 汉义生物科技（北京）有限公司 | 一种含有大麻二酚或大麻提取物和咖啡因的组合物及其应用 |
| US20200172841A1 (en) * | 2018-12-04 | 2020-06-04 | Donald F. Wilkes | Alcohol-free wine beverage |
-
2020
- 2020-06-18 GB GBGB2009321.7A patent/GB202009321D0/en not_active Ceased
-
2021
- 2021-06-16 JP JP2022578719A patent/JP2023530500A/ja active Pending
- 2021-06-16 MX MX2022016038A patent/MX2022016038A/es unknown
- 2021-06-16 US US18/002,437 patent/US20230225986A1/en active Pending
- 2021-06-16 AU AU2021291128A patent/AU2021291128A1/en active Pending
- 2021-06-16 KR KR1020227044124A patent/KR20230026337A/ko active Pending
- 2021-06-16 CN CN202180042463.2A patent/CN115916168A/zh active Pending
- 2021-06-16 WO PCT/GB2021/051520 patent/WO2021255446A1/en not_active Ceased
- 2021-06-16 CA CA3181694A patent/CA3181694A1/en active Pending
- 2021-06-16 EP EP21736654.1A patent/EP4167980B1/en active Active
- 2021-06-17 TW TW110122055A patent/TW202214217A/zh unknown
- 2021-06-17 GB GB2108690.5A patent/GB2598187A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP4167980A1 (en) | 2023-04-26 |
| AU2021291128A1 (en) | 2022-12-01 |
| CA3181694A1 (en) | 2021-12-23 |
| KR20230026337A (ko) | 2023-02-24 |
| CN115916168A (zh) | 2023-04-04 |
| GB202009321D0 (en) | 2020-08-05 |
| TW202214217A (zh) | 2022-04-16 |
| WO2021255446A1 (en) | 2021-12-23 |
| GB202108690D0 (en) | 2021-08-04 |
| US20230225986A1 (en) | 2023-07-20 |
| GB2598187A (en) | 2022-02-23 |
| JP2023530500A (ja) | 2023-07-18 |
| EP4167980B1 (en) | 2025-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ764587A (en) | Use of cannabinoids in the treatment of epilepsy | |
| MX2023012352A (es) | Uso de cannabinoides en el tratamiento de convulsiones asociadas al sindrome de lennox-gastaut. | |
| MX2020007784A (es) | Uso de cannabinoides en el tratamiento de la epilepsia. | |
| EP4640275A3 (en) | USE OF CANNABIDIOL IN THE TREATMENT OF ANGELMAN SYNDROME ANXIETY | |
| MX2021008702A (es) | Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia. | |
| MX383835B (es) | Uso de cannabidiol en el tratamiento del complejo de escleroris tuberosa. | |
| MX2021009646A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| BR112021022139A2 (pt) | Preparação de canabidiol, e, método para tratar um paciente que sofre de espasmos epilépticos | |
| CO2019013887A2 (es) | Composiciones y tratamientos para el trastorno del sueño | |
| MX379255B (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| MX2021006094A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| MX2020003934A (es) | Uso de cannabidiol en combinacion con agonistas del receptor 5-ht2b o anfetamina en el tratamiento de la epilepsia. | |
| GB201111261D0 (en) | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders | |
| RU2012103603A (ru) | Применение одного или комбинации фитоканнабиноидов для лечения эпилепсии | |
| MX2022016038A (es) | Uso de cannabidiol en el tratamiento de la epilepsia. | |
| CA2582289C (en) | Inhibition of tumour cell migration | |
| US10596159B2 (en) | Method and composition for treating cachexia and eating disorders | |
| GB2468828A (en) | Use of cannabinoids in combination with an anti-psychotic medicament | |
| GB2564459A8 (en) | Use of cannabinoids in the treatment of a neurodegenerative disease or disorder | |
| BR112022021640A2 (pt) | Usos e formulações de canabinoides | |
| Farkhondeh et al. | Impact of cannabis-based medicine on alzheimer’s disease by focusing on the amyloid β-modifications: A systematic study | |
| BR0010515A (pt) | Sistema terapêutico de ministração transdérmica, processo para mascarar um odor desagrádavel e uso de um óleo essencial em um sistema terapéutico de ministração transdérmica | |
| MY208105A (en) | Compositions and methods for treating sexual dysfunction and enhancing sexual response and pleasure | |
| MX2022010960A (es) | Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides. | |
| Tanganeli et al. | The endocannabinoid system and orofacial pains: updates and perspectives |